Every 8-K that Karyopharm Therapeutics Inc (KPTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KPTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPTI filings page.
Karyopharm Therapeutics Inc. (KPTI) reported that it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis. The company has also requested Priority Review, which, if granted, could shorten the FDA review to about six months.
The submission draws in part on Phase 3 SENTRY trial data, including what the company describes as a promising signal of overall survival and use of spleen volume reduction ≥35% (SVR35) as a surrogate endpoint. Karyopharm plans to use long-term overall survival data from SENTRY to verify clinical benefit for potential conversion from accelerated to traditional approval. The company also reiterates significant risks, including that substantial doubt exists regarding its ability to continue as a going concern.
Karyopharm Therapeutics Inc. reported second quarter 2026 total revenue of $33.4 million, down from $37.9 million a year earlier, with U.S. XPOVIO net product revenue rising modestly to $30.8 million. License and other revenue fell sharply to $2.6 million as a Menarini R&D funding obligation expired.
R&D and SG&A expenses declined year over year, but the company still posted a net loss of $67.0 million, driven by an operating loss of $22.5 million and $44.5 million in non-operating expense, including $13.1 million of interest and $32.1 million of non-cash derivative and warrant-related expense. Cash, cash equivalents, restricted cash and investments totaled $65.4 million at June 30, 2026.
The company reaffirmed 2026 guidance for total revenue of $130–$150 million and U.S. XPOVIO revenue of $115–$130 million, and expects R&D plus SG&A of $230–$245 million. Management is actively evaluating financing opportunities and strategic alternatives as it faces a $15.8 million senior term-loan principal payment due September 10, 2026 and a $10.0 million minimum liquidity covenant that could be breached absent additional actions. Karyopharm remains on track to submit an August sNDA under the Accelerated Approval pathway for selinexor plus ruxolitinib in myelofibrosis, supported by positive Phase 3 SENTRY data, while its Phase 3 endometrial cancer trial did not meet its primary endpoint.
Karyopharm Therapeutics reported topline Phase 3 results from its XPORT-EC-042 trial of selinexor maintenance in TP53 wild-type advanced or recurrent endometrial cancer; the study did not meet its primary endpoint of progression free survival.
In the modified intent-to-treat population (n=236), median PFS was 12.75 months with selinexor versus 7.43 months with placebo (hazard ratio 0.76; one-sided p=0.0791), and safety was consistent with the established profile, with no new signals. Ongoing selinexor studies in other indications are unchanged.
Karyopharm plans an August 2026 supplemental New Drug Application seeking FDA accelerated approval of selinexor plus ruxolitinib in myelofibrosis, based on Phase 3 SENTRY data showing statistically significant SVR35 spleen responses at week 24, supportive survival and biomarker findings, and overall safety. The company is also exploring financing transactions and strategic alternatives with advisors, including Centerview Partners.
Karyopharm Therapeutics Inc. approved a new 2026 Leadership Cash Retention Program on July 13, 2026 for certain employees, including all named executive officers and the Chief Financial Officer. The program is intended to incentivize retention of key employees during a period in which the company is expecting several meaningful catalysts.
The program replaces previously guaranteed amounts under the company’s Annual Bonus Plan for 2026. Lump-sum cash retention awards will be paid as follows: Richard Paulson, President and CEO, $1,725,000; Stuart Poulton, EVP and Chief Development Officer, $640,000; Dr. Reshma Rangwala, EVP, Chief Medical Officer and Head of Research, $725,000; and Lori Macomber, EVP, Chief Financial Officer and Treasurer, $625,000.
Awards may be subject to repayment if employment ends for any reason other than by the company without cause, by the executive for good reason, or due to death or permanent disability, before the earlier of 12 months from the payment date or 30 days after a qualifying corporate event. Amounts paid under this program will reduce payments due under previously agreed severance arrangements.
Karyopharm Therapeutics Inc. reported that stockholders approved an amendment to its 2022 Equity Incentive Plan, adding 3,000,000 shares of common stock for equity awards. Stockholders also increased shares available under the Amended & Restated 2013 Employee Stock Purchase Plan by 1,400,000 shares.
The Board’s Compensation Committee adopted a broad-based retention program using performance-based restricted stock units, covering an aggregate of 3,838,380 PSUs for eligible employees. Awards include 343,000 PSUs for each of two tranches to President and CEO Richard Paulson, with vesting tied to specified clinical and other milestones and continued service.
Stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Karyopharm Therapeutics reported first quarter 2026 results with total revenue of $35.1 million, up from $30.0 million a year earlier. U.S. XPOVIO net product revenue rose to $29.2 million from $21.1 million, helped by lower gross-to-net adjustments, while royalty revenue increased to $1.9 million.
Operating loss improved to $26.8 million and net loss narrowed to $22.4 million, or $1.02 per basic share. The company reaffirmed 2026 total revenue guidance of $130–$150 million and U.S. XPOVIO revenue of $115–$130 million, and expects its cash to fund operations into late in the third quarter of 2026.
Karyopharm highlighted clinical milestones, including completion of enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial and positive Phase 3 SENTRY myelofibrosis results that met the spleen volume reduction endpoint but not the symptom score endpoint. Topline data readouts from multiple Phase 3 trials are expected in mid to second half of 2026.
Karyopharm Therapeutics Inc. completed a private placement with RA Capital Management, selling 1,030,354 common shares at $6.785 each and pre-funded warrants for up to 3,391,164 shares at $6.7849, plus warrants for 4,421,518 shares at a $10.00 exercise price, for gross proceeds of about $30 million.
In March 2026 it also sold 2,994,441 common shares under its at-the-market sales agreement for net proceeds of about $19.8 million. After these transactions, it had 22,543,316 common shares outstanding and pre-funded warrants for 4,005,556 shares, and expects its liquidity to fund operations into late in the third quarter of 2026.
Karyopharm Therapeutics entered a private placement with RA Capital, selling 1,030,354 common shares, 3,391,164 pre-funded warrants, and 4,421,518 common warrants, for about $30 million in gross proceeds, plus about $44 million if all warrants are exercised. In March 2026 it also sold 1,100,844 shares via its at-the-market program for about $9.6 million net, and had 19,618,032 shares outstanding as of March 23, 2026. Closing the private placement will satisfy the capital-raise trigger for its amended credit and forbearance agreements.
The Phase 3 SENTRY myelofibrosis trial met the spleen-volume co-primary endpoint, with 50% of patients on selinexor plus ruxolitinib achieving SVR35 at week 24 versus 28% on ruxolitinib alone, but did not show a statistically significant symptom-score benefit. A nominally significant overall-survival signal was reported with a hazard ratio of 0.43. Safety showed more grade 3+ adverse events (70% vs 50%) and higher discontinuations (15% vs 9%). Karyopharm will seek FDA feedback on a supplemental NDA. The company will voluntarily withdraw the accelerated approval for the DLBCL indication of XPOVIO due to feasibility of completing the confirmatory trial, noting minimal revenue from that use.
Karyopharm Therapeutics amended its credit agreement and entered a broad forbearance arrangement to manage liquidity while it continues to face substantial doubt about its ability to continue as a going concern. The changes aim to extend its cash runway beyond the second quarter of 2026 and past expected top-line data from the Phase 3 XPORT-EC 042 trial, if conditions are met.
The amendment allows June 30, 2026 cash interest under the credit facility to be paid in kind and moves a June 10, 2026 principal payment to September 10, 2026 if the company raises at least $25.0 million in common stock proceeds before June 10, 2026, defined as the Capital Raise Trigger. It keeps the minimum consolidated liquidity covenant at $10.0 million through October 10, 2026, excluding qualifying equity proceeds from increasing that threshold, and extends a 5% prepayment premium potentially through May 8, 2027.
Through a separate forbearance agreement, all lenders, holders of the company’s 9.00% convertible notes due 2028 and 2029, and the revenue interest investors agree, once the Capital Raise Trigger occurs, to temporarily refrain from exercising certain rights related to missed June 30, 2026 cash interest payments and related minimum liquidity covenant issues, with forbearance periods running to September 30, 2026 and October 10, 2026, respectively.
Karyopharm Therapeutics Inc. obtained stockholder approval at a special meeting to significantly increase its authorized share capital. The amendment raises total authorized capital stock from 58,333,333 to 111,000,000 shares and authorized common stock from 53,333,333 to 106,000,000 shares.
The Authorized Shares Proposal passed with 9,436,123 votes for, 3,213,329 against and 25,465 abstaining. A related adjournment proposal was also approved but not used. The company filed a Certificate of Amendment in Delaware on February 18, 2026 to put the share increase into effect.
Karyopharm Therapeutics reported essentially flat 2025 revenue while remaining deeply loss-making and heavily leveraged. Total revenue was $146.1 million, up slightly from $145.2 million, with U.S. XPOVIO net product revenue of $114.9 million. Loss from operations improved to $90.7 million from $119.4 million as R&D and SG&A were reduced, but net loss widened sharply to $196.0 million, driven largely by a $62.4 million loss on extinguishment of debt and higher interest expense.
Cash, cash equivalents, restricted cash and investments fell to $64.1 million at year-end 2025, and the company expects its existing liquidity plus cash flows to fund operations only into the second quarter of 2026. For 2026, Karyopharm guides total revenue to $130–$150 million and U.S. XPOVIO net product revenue to $115–$130 million, against planned R&D and SG&A of $230–$245 million, implying continued operating losses.
Strategically, management highlights late-stage pipeline catalysts: top-line data from the Phase 3 SENTRY myelofibrosis trial expected in March 2026, and top-line data from the Phase 3 XPORT-EC-042 endometrial cancer trial expected in mid-2026, positioning 2026 as a pivotal year for selinexor’s potential label and revenue expansion.
Karyopharm Therapeutics released preliminary, unaudited 2025 results, expecting total revenue of approximately $145 million for the year, including license and royalty income. For the quarter ended December 31, 2025, it anticipates total revenue of about $33 million.
The company expects U.S. XPOVIO net product revenue of roughly $115 million for 2025, including about $32 million in the fourth quarter. Karyopharm also projects cash, cash equivalents, restricted cash and investments of around $64 million as of December 31, 2025, and believes its existing liquidity, together with expected XPOVIO sales and license revenue, will fund planned operations into the second quarter of 2026.
Karyopharm Therapeutics (KPTI) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025, and a previously announced, publicly available conference call to discuss the results and company updates.
The accompanying press release was furnished as Exhibit 99.1 and is incorporated by reference. The company noted that this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
Karyopharm Therapeutics (KPTI) completed a set of financing transactions. The company issued 9.00% senior secured convertible notes in two series: $15.0 million aggregate principal amount due 2028 and $103.5 million aggregate principal amount due 2029. It also borrowed $12.5 million under its existing credit and guaranty agreement.
The company entered into indentures for each note series with Wilmington Savings Fund Society as trustee and collateral agent and executed related registration rights agreements with term loan lenders. Exhibits include a first amendment and waiver to the credit agreement, a note purchase agreement, exchange agreements, warrant forms, a pre-funded warrant form, and a sixth amendment to the revenue interest financing agreement.
Shares outstanding were 15,926,939 as of October 14, 2025, assuming no exercise of pre-funded warrants or warrants and no conversions of the new convertible notes.
Karyopharm Therapeutics, Inc. disclosed an amendment and related licensing activity centered on its oncology drug selinexor. Under an Amendment No. 4 dated August 7, 2025, Karyopharm granted Berlin-Chemie AG (an affiliate of the Menarini Group) a non-exclusive license to develop and an exclusive license to commercialize selinexor for human oncology indications across Europe (including the United Kingdom), Latin America, certain Middle East and Africa regions and other specified countries. The filing also references exchange transactions involving pre-funded warrants and warrants to purchase common stock (including warrants for an aggregate of 2,502,151 shares and pre-funded warrants for 552,164 and 1,404,087 shares) and notes a correction to a prior 10-Q paragraph. The notice was accompanied by a press release dated October 8, 2025.
Karyopharm Therapeutics Inc. reported that board member Dr. Mansoor Raza Mirza has resigned from its Board of Directors, effective September 8, 2025, citing competing professional demands. The company states his resignation is not due to any disagreement regarding its operations, policies or practices.
Dr. Mirza is also resigning as Chief Oncologist at Copenhagen University National Medical Center effective October 1, 2025 to focus on a new executive role in industry. In connection with his departure from the board, the consulting agreement between Karyopharm and Mirza Consulting, an entity wholly owned by Dr. Mirza, was terminated effective September 8, 2025.
Karyopharm Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The Form 8-K states the full press release with details is furnished as Exhibit 99.1 and is incorporated by reference into the report.
The filing clarifies that the information in this report and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability or automatic incorporation by reference in other Securities Act or Exchange Act filings. The Form 8-K itself does not include the financial figures in-line; investors must review Exhibit 99.1 for the substantive results.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) filed a Form 8-K on 11-Jul-2025 detailing material liquidity and operational actions.
The company disclosed that it held confidential discussions with new and existing investors to extend its cash runway; however, no financing agreement has been reached. To comply with confidentiality agreements, it published the related investor presentation (the “Cleansing Materials”) as Exhibit 99.1.
The Board is actively evaluating strategic alternatives that could include a merger or sale of the company, in- or out-of-court restructurings, or refinancing of existing debt. Management cautions that there is no assurance any transaction will occur or what terms might apply.
To conserve cash, Karyopharm is implementing a 20 % workforce reduction, with one-time charges expected to be immaterial. The company intends to keep supporting commercial sales of XPOVIO for multiple myeloma and to advance ongoing Phase 3 trials in myelofibrosis and endometrial cancer.
The filing reiterates forward-looking risk factors, including substantial doubt about the company’s ability to continue as a going concern absent additional capital.